Is non-biological treatment of rheumatoid arthritis as good as biologics?  

作　　者：Jyoti Ranjan Parida Durga Prasanna Misra Anupam Wakhlu Vikas Agarwal 

机构地区：[1]Department of Clinical Immunology,Sanjay Gandhi Postgraduate Institute of Medical Sciences [2]Department of Rheumatology,King George’s Medical University

出　　处：《World Journal of Orthopedics》2015年第2期278-283,共6页世界骨科杂志（英文版）

摘　　要：The management of rheumatoid arthritis(RA) in the past three decades has undergone a paradigm shift from symptomatic relief to a "treat-to-target" approach. This has been possible through use of various conventional and biologic disease modifying anti-rheumatic drugs(DMARDs) which target disease pathogenesis at a molecular level. Cost and infection risk preclude regular use of biologics in resource-constrained settings. In therecent years, evidence has emerged that combination therapy with conventional DMARDs is not inferior to biologics in the management of RA and is a feasible cost-effective option.The management of rheumatoid arthritis(RA) in the past three decades has undergone a paradigm shift from symptomatic relief to a "treat-to-target" approach. This has been possible through use of various conventional and biologic disease modifying anti-rheumatic drugs(DMARDs) which target disease pathogenesis at a molecular level. Cost and infection risk preclude regular use of biologics in resource-constrained settings. In therecent years, evidence has emerged that combination therapy with conventional DMARDs is not inferior to biologics in the management of RA and is a feasible cost-effective option.

关 键 词：Rheumatoid arthritis Disease modifying drugs BIOLOGICS Methotrexate SULFASALAZINE LEFLUNOMIDE CYCLOSPORINE HYDROXYCHLOROQUINE Tumor necrosis factor Remission RADIOLOGIC outcome 

分 类 号：R593.22[医药卫生—内科学]